May 27, 2020 -- Thermo Fisher Scientific has entered into a long-term lease agreement with CSL to operate a new biologics manufacturing facility in Lengnau, Switzerland.
Thermo will support the manufacturing of CSL's product for hemophilia patients at the site, which is set to be completed in mid-2021. Eventually, Thermo will provide services including drug product development, biologics manufacturing, sterile fill-finish, packaging, and logistics of clinical trials. Thermo plans to expand the use of the site to include additional biopharma customers.
The site will feature highly flexible bioproduction technologies, including single-use and stainless steel, to provide a pathway from development to large-scale production. Over time, Thermo plans to expand the use of the site to include additional biopharmaceutical customers.
Copyright © 2020 scienceboard.net